ArticleFrontiers in immunology2019
Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Small is big: growing impact of small molecule mass spectrometry in infectious disease drug development.mSphere · 2026Review
- Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology.The Journal of experimental medicine · 2026Article
- Long COVID involves activation of proinflammatory and immune exhaustion pathways.Nature immunology · 2026Observational
- Predictive metabolite signatures for risk of progression to active TB from QuantiFERON supernatants of household contacts of TB patients.Emerging microbes & infections · 2025Article
- The Evolving Landscape of Host Biomarkers for Diagnosis and Monitoring of Tuberculosis.Biomedicines · 2025Review
- Animal models in tuberculosis metabolomics: a systematic review of current evidence and the road to translational relevance.Frontiers in molecular biosciences · 2025Review
- Understanding the Spectrum and Management of Post-Tuberculosis Lung Disease: A Comprehensive Review.Cureus · 2024Review
- Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study.Infection and drug resistance · 2024Article
- Metabolomics and lipidomics strategies in modern drug discovery and development.Drug discovery today · 2023Review
- Biomarker discovery for tuberculosis using metabolomics.Frontiers in molecular biosciences · 2023Review
- Advancing personalized medicine for tuberculosis through the application of immune profiling.Frontiers in cellular and infection microbiology · 2023Review
- The quest for vaccine-induced immune correlates of protection against tuberculosis.Vaccine insights · 2022Article
- It Takes a Village: The Multifaceted Immune Response toFrontiers in immunology · 2022Review
- Host lipidome and tuberculosis treatment failure.The European respiratory journal · 2022Article
- Tuberculosis alters immune-metabolic pathways resulting in perturbed IL-1 responses.Frontiers in immunology · 2022Article
- After 100 Years of BCG Immunization against Tuberculosis, What Is New and Still Outstanding for This Vaccine?Vaccines · 2021Review
- Increased UBE2L6 regulated by type 1 interferon as potential marker in TB.Journal of cellular and molecular medicine · 2021Article
- BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines.Immunological reviews · 2021Review
- Metabolic Versatility ofMetabolites · 2021Review
- Plasma Metabolomics Reveals Dysregulated Metabolic Signatures in HIV-Associated Immune Reconstitution Inflammatory Syndrome.Frontiers in immunology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 6 countries.
Funding
Abstract
There remains a pressing need for biomarkers that can predict who will progress to active tuberculosis (TB) after exposure to Mycobacterium tuberculosis (MTB) bacterium. By analyzing cohorts of household contacts of TB index cases (HHCs) and a stringent non-human primate (NHP) challenge model, we evaluated whether integration of blood transcriptional profiling with serum metabolomic profiling can provide new understanding of disease processes and enable improved prediction of TB progression. Compared to either alone, the combined application of pre-existing transcriptome- and metabolome-based signatures more accurately predicted TB progression in the HHC cohorts and more accurately predicted disease severity in the NHPs. Pathway and data-driven correlation analyses of the integrated transcriptional and metabolomic datasets further identified novel immunometabolomic signatures significantly associated with TB progression in HHCs and NHPs, implicating cortisol, tryptophan, glutathione, and tRNA acylation networks. These results demonstrate the power of multi-omics analysis to provide new insights into complex disease processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.